Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1992 |
Mertansine
DM1,Maytansinoid DM1 |
Microtubule Associated | Cytoskeletal Signaling |
Mertansine (DM1) 是一种微管蛋白抑制剂,也是一种抗体可缀合的美登木素生物碱。它通过连接体连接到单克隆抗体上,形成抗体偶联药物。 | |||
T13766 |
Maytansinoid DM4
|
Others | Others |
Maytansinoid DM4, a thiol-containing maytansine derivative, is a highly potent cytotoxic moiety utilized in ADC applications. | |||
T11058 |
DM3
Maytansinoid DM3 |
Others | Others |
DM3 (Maytansinoid DM3) is a maytansine mimic containing disulfide or thiol groups and a tubulin inhibitor. It is the cytotoxic part of antibody-drug conjugates (ADCs) . | |||
T77874 |
Maytansinoid B
|
||
Maytansinoid B 是一种ADC Cytotoxin,用于形成与抗体结合的Antibody-Drug Conjugates (ADCs)。它是一种抗有丝分裂剂,能够结合微管蛋白并阻断其组装,诱导细胞周期在G2/M阶段停滞,进而触发细胞凋亡(apoptosis)。 | |||
T74975 |
Zn-DPA-maytansinoid conjugate 1
|
||
Zn-DPA-maytansinoid conjugate 1 为一种靶向小分子免疫检查点的类美坦素偶联物。其能持续诱导肿瘤生长消退,并激活肿瘤微环境(TME),转化为“炎热肿瘤”。 | |||
T21408 |
DM1-SMe
DM1-SSMe |
Microtubule Associated | Cytoskeletal Signaling |
DM1-SMe (DM1-SSMe) 是美登木素微管的有效抑制剂。 DM1-SMe 的效力是母体药物美登素的 3 至 10 倍,在一组人类肿瘤细胞系中,DM1-SMe 的 IC50 为 0.003 至 0.01 nM。 | |||
T82021 |
Izeltabart
IMGC-936 |
||
Izeltabart(IMGC-936)是一款针对ADAM9的基于Maytansinoid的ADC,由与DM21-C位点特异性偶联的高亲和力人源化抗体构成,使Maytansinoid微管破坏载体通过稳定的三肽连接子进行传递,达到药物-抗体比约为2.0。Izeltabart在ADAM9阳性人类肿瘤细胞系上显示出明显的细胞毒性,并在动物异种移植肿瘤模型中展现出显著的抗肿瘤效果。 | |||
T77872 |
S-Me-DM4
|
||
S-Me-DM4是DM4在胞内酶作用下发生S-甲基化反应形成的代谢产物。DM4本身是一种具有强细胞毒性的含硫醇类微管解聚剂,并可作为ADC Cytotoxin分子应用。 | |||
T82173 |
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
|
||
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM 是一种用于抗体偶联药物(ADC)的药物连接体。其中DM代表了maytansinoid组分。 | |||
T17793 |
DBCO-PEG4-Ahx-DM1
|
Others | Others |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs). | |||
T17832 |
DM1-PEG4-DBCO
|
Others | Others |
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid. | |||
T77907 |
Tusamitamab ravtansine
HuMAb2-3-SPDB-DM4,SAR-408701 |
||
Tusamitamab ravtansine (SAR-408701) 是一款针对CEACAM5的人源化单克隆抗体与DM4细胞毒性药物经活性分子连接而成的抗体-药物偶联物(ADC),专门靶向CEACAM5表达的肿瘤细胞。 |